Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center

  • Jeong, Hyung Joo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Ahn, Yo Han (Department of Pediatrics, Hallym University Kangnam Sacred Heart Hospital) ;
  • Park, Eujin (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Choi, Youngrok (Department of Surgery, Seoul National University College of Medicine) ;
  • Yi, Nam-Joon (Department of Surgery, Seoul National University College of Medicine) ;
  • Ko, Jae Sung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Min, Sang Il (Department of Surgery, Seoul National University College of Medicine) ;
  • Ha, Jong Won (Department of Surgery, Seoul National University College of Medicine) ;
  • Ha, Il-Soo (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Cheong, Hae Il (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kang, Hee Gyung (Department of Pediatrics, Seoul National University College of Medicine)
  • Received : 2016.08.29
  • Accepted : 2016.10.25
  • Published : 2017.03.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To evaluate the clinical spectrum of posttransplantation lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT) in children. Methods: We retrospectively reviewed the medical records of 18 patients with PTLD who underwent liver (LT) or kidney transplantation (KT) between January 1995 and December 2014 in Seoul National University Children's Hospital. Results: Eighteen patients (3.9% of pediatric SOTs; LT:KT, 11:7; male to female, 9:9) were diagnosed as having PTLD over the last 2 decades (4.8% for LT and 2.9% for KT). PTLD usually presented with fever or gastrointestinal symptoms in a median period of 7 months after SOT. Eight cases had malignant lesions, and all the patients except one had evidence of Epstein-Barr virus (EBV) involvement, assessed by using in situ hybridization of tumor tissue or EBV viral load quantitation of blood. Remission was achieved in all patients with reduction of immunosuppression and/or rituximab therapy or chemotherapy, although 1 patient had allograft kidney loss and another died from complications of chemotherapy. The first case of PTLD was encountered after the introduction of tacrolimus for pediatric SOT in 2003. The recent increase in PTLD incidence in KT coincided with modification of clinical practice since 2012 to increase the tacrolimus trough level. Conclusion: While the outcome was favorable in that all patients achieved complete remission, some patients still had allograft loss or mortality. To prevent PTLD and improve its outcome, monitoring for EBV infection is essential, which would lead to appropriate modification of immunosuppression and enhanced surveillance for PTLD.

Keywords

References

  1. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, Krawczyk M, Lerut J, Paczek L. Post-transplant lymphoproliferative disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Transplant 2010;25:2089-98. https://doi.org/10.1093/ndt/gfq231
  2. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993;342:1514-6. https://doi.org/10.1016/S0140-6736(05)80084-4
  3. Caillard S, Lelong C, Pessione F, Moulin B; French PTLD Working Group. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant 2006;6:2735-42. https://doi.org/10.1111/j.1600-6143.2006.01540.x
  4. Smets F, Latinne D, Bazin H, Reding R, Otte JB, Buts JP, et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002;73:1603-10. https://doi.org/10.1097/00007890-200205270-00014
  5. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4: 222-30. https://doi.org/10.1046/j.1600-6143.2003.00325.x
  6. Heo JS, Park JW, Lee KW, Lee SK, Joh JW, Kim SJ, et al. Posttransplantation lymphoproliferative disorder in pediatric liver transplantation. Transplant Proc 2004;36:2307-8. https://doi.org/10.1016/j.transproceed.2004.08.138
  7. Yoon SO, Yu E, Cho YM, Suh C, Kim KM, Han DJ, et al. Post-transplant lymphoproliferative disorders: clinicopathological analysis of 43 cases in a single center, 1990-2009. Clin Transplant 2012;26: 67-73. https://doi.org/10.1111/j.1399-0012.2010.01392.x
  8. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (FR): International Agency for Research on Cancer, 2008.
  9. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94. https://doi.org/10.1056/NEJM199309303291402
  10. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71:1076-88. https://doi.org/10.1097/00007890-200104270-00012
  11. Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant 2011;11:336-47. https://doi.org/10.1111/j.1600-6143.2010.03387.x
  12. Park ES, Kim H, Lee JW, Lim JY, Kang HJ, Park KD, et al. Treatment outcomes in children with Burkitt lymphoma and L3 acute lymphoblastic leukemia treated using the lymphoma malignancy B protocol at a single institution. Korean J Hematol 2011;46:96-102. https://doi.org/10.5045/kjh.2011.46.2.96
  13. Kim JM, Kim KM, Yi NJ, Choe YH, Kim MS, Suh KS, et al. Pediatric liver transplantation outcomes in Korea. J Korean Med Sci 2013; 28:42-7. https://doi.org/10.3346/jkms.2013.28.1.42
  14. Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, et al. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant 2013;27:E491-7. https://doi.org/10.1111/ctr.12172
  15. Park MH, Whang DH, Kang SJ, Han KS. HLA-A*02 allele frequencies and haplotypic associations in Koreans. Tissue Antigens 2000;55:250-6. https://doi.org/10.1034/j.1399-0039.2000.550308.x
  16. Evens AM, David KA, Helenowski I, Nelson B, Kaufman D, Kircher SM, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era. J Clin Oncol 2010;28:1038-46. https://doi.org/10.1200/JCO.2009.25.4961
  17. Suresh S, Lee BE, Robinson JL, Akinwumi MS, Preiksaitis JK. A risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients. Pediatr Transplant 2016;20:970-980. https://doi.org/10.1111/petr.12786
  18. Reshef R, Luskin MR, Kamoun M, Vardhanabhuti S, Tomaszewski JE, Stadtmauer EA, et al. Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients. Am J Transplant 2011;11:817-25. https://doi.org/10.1111/j.1600-6143.2011.03454.x
  19. Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation 2006;82:1093-100. https://doi.org/10.1097/01.tp.0000235889.05171.12
  20. Pourfarziani V, Einollahi B, Taheri S, Nemati E, Nafar M, Kalantar E. Associations of Human Leukocyte Antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant 2007;12:16-22.
  21. Lustberg ME, Pelletier RP, Porcu P, Martin SI, Quinion CD, Geyer SM, et al. Human leukocyte antigen type and posttransplant lymphoproliferative disorder. Transplantation 2015;99:1220-5. https://doi.org/10.1097/TP.0000000000000487
  22. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012;13:196-206. https://doi.org/10.1016/S1470-2045(11)70300-X
  23. Fernandez MC, Bes D, De Davila M, Lopez S, Cambaceres C, Dip M, et al. Post-transplant lymphoproliferative disorder after pediatric liver transplantation: characteristics and outcome. Pediatr Transplant 2009;13:307-10. https://doi.org/10.1111/j.1399-3046.2008.00914.x
  24. Soriano-Lopez DP, Alcantar-Fierros JM, Hernandez-Plata JA, Gonzalez-Jorge AL, Velazquez-Ramos S, Flores-Hernandez MA, et al. A scheduled program of molecular screening for epstein-barr virus decreases the incidence of post-transplantation lymphoproliferative disease in pediatric liver transplantation. Transplant Proc 2016;48:654-7. https://doi.org/10.1016/j.transproceed.2016.02.031
  25. Jang JY, Kim KM, Lee YJ, Lee SG, Chi HS. Quantitative Epstein-Barr virus viral load monitoring in pediatric liver transplantation. Transplant Proc 2008;40:2546-8. https://doi.org/10.1016/j.transproceed.2008.07.014
  26. Narkewicz MR, Green M, Dunn S, Millis M, McDiarmid S, Mazariegos G, et al. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience. Liver Transpl 2013;19: 730-40. https://doi.org/10.1002/lt.23659
  27. Lee TC, Savoldo B, Rooney CM, Heslop HE, Gee AP, Caldwell Y, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005;5:2222-8. https://doi.org/10.1111/j.1600-6143.2005.01002.x

Cited by

  1. Multiple drugs : Various toxicities: 18 case reports vol.1647, pp.1, 2017, https://doi.org/10.1007/s40278-017-28906-0
  2. Pediatric Gastrointestinal Posttransplant Lymphoproliferative Disorder: Incidence, Clinical Characteristics, and Impact of Major Surgical Interventions Upon Overall Survival vol.40, pp.6, 2017, https://doi.org/10.1097/mph.0000000000001228
  3. Pediatric Outcomes in Transplant: PersOnaliSing Immunosuppression To ImproVe Efficacy (POSITIVE Study): The Collaboration and Design of a National Transplant Precision Medicine Program vol.4, pp.12, 2018, https://doi.org/10.1097/txd.0000000000000842
  4. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia vol.34, pp.30, 2019, https://doi.org/10.3346/jkms.2019.34.e203
  5. A multicenter survey on post‐transplant lymphoproliferative disorders in pediatric heart transplant recipients: A case for development of consensus guidelines for screening, surveillance, and tr vol.24, pp.5, 2017, https://doi.org/10.1111/petr.13730
  6. Malignancy after Pediatric Kidney Transplantation: The 30-Year Experience of a Single Center vol.24, pp.2, 2017, https://doi.org/10.3339/jkspn.2020.24.2.75
  7. De-novo malignancies after kidney transplantation: A long-term observational study vol.15, pp.11, 2020, https://doi.org/10.1371/journal.pone.0242805
  8. Course of renal allograft function after diagnosis and treatment of post‐transplant lymphoproliferative disorders in pediatric kidney transplant recipients vol.25, pp.6, 2017, https://doi.org/10.1111/petr.14042